The North America Fibromyalgia Treatment Market would witness market growth of 3.7% CAGR during the forecast period (2023-2030).
The complexity of fibromyalgia is the reason why diagnosis and treatment are required to take a multifaceted approach, combining medical practitioners from different specialties to address the disease's many symptoms and comorbidities. In addition to several drugs, it may also be treated with dietary and lifestyle changes. The symptoms of fibromyalgia include extreme pain, difficulty sleeping, tiredness, irritability, and memory loss. Fibromyalgia is commonly accompanied by several other symptoms as well. Only three drugs have been approved for use, particularly in treating fibromyalgia, at this time.
Because of this, products that are off-label are utilized more frequently. But increased research and development in pain management is anticipated to support using approved medications for the illness indication. The burden of chronic pain is mostly to blame for the market's expansion. Researchers have found that fibromyalgia changes how the brain and spinal cord process painful and non-painful signals, increasing the intensity of painful sensations. The increased incidence of chronic pain conditions like fibromyalgia is anticipated to increase demand for different treatment alternatives, ultimately fueling market expansion during the anticipated period.
Mexico's road traffic fatalities have remained consistently high in recent years, despite the country's population of nearly 130 million people. There were over 16,000 recorded deaths in 2019. Due to a lack of accountability among various sectors and institutions, Mexico's federal government struggled to achieve intersectoral coordination and progress in road safety, resulting in fatal and non-fatal traffic injuries. The increasing number of road accidents in the region will create growth opportunities for the market as FM can occur to people involved in road accidents, thereby boosting the market expansion in the region.
The US market dominated the North America Fibromyalgia Treatment Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,022.1 million by 2030. The Canada market is poised to grow at a CAGR of 6.1% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 5.1% during (2023 - 2030).
Based on Drug Class, the market is segmented into Anticonvulsants, Antidepressants, Muscle Relaxants and Others. Based on Distribution Channel, the market is segmented into Drug stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Fibromyalgia Treatment Market is Projected to reach USD 4 Billion by 2030, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Novartis AG, Eli Lilly And Company, Amneal Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Zydus Lifesciences Ltd., Lupin Limited, Abbott Laboratories, Viatris, Inc., and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
